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Cell cycle-dependent activation of Ras
Stephen J. Taylor and David Shalloway
Background: Ras proteins play an essential role in the transduction of signals
from a wide range of cell-surface receptors to the nucleus. These signals may
promote cellular proliferation or differentiation, depending on the cell
background. It is well established that Ras plays an important role in the
transduction of mitogenic signals from activated growth-factor receptors, leading
to cell-cycle entry. However, important questions remain as to whether Ras
controls signalling events during cell-cycle progression and, if so, at which point
in the cell-cycle it is activated.
Results: To address these questions we have developed a novel, functional
assay for the detection of cellular activated Ras. Using this assay, we found that
Ras was activated in HeLa cells, following release from mitosis, and in NIH 3T3
fibroblasts, following serum-stimulated cell-cycle entry. In each case, peak Ras
activation occurred in mid-G1 phase. Ras activation in HeLa cells at mid-G1
phase was dependent on RNA and protein synthesis and was not associated
with tyrosine phosphorylation of Shc proteins and their binding to Grb2.
Significantly, activation of Ras and the extracellular-signal regulated (ERK) sub-
group of mitogen-activated protein kinases were not temporally correlated during
G1-phase progression.
Conclusions: Activation of Ras during mid-G1 phase appears to differ in many
respects from its rapid activation by growth factors, suggesting a novel
mechanism of regulation that may be intrinsic to cell-cycle progression.
Furthermore, the temporal dissociation between Ras and ERK activation suggests
that Ras targets alternate effector pathways during G1-phase progression.
Background
Ras proteins act as molecular switches that relay
proliferative signals from cell-surface receptors to the
nucleus and cytoskeleton. Specifically, the activation of
Ras by the binding of GTP is required for the ability of
many growth factors and cytokines to induce non-
proliferating cells to enter G1 phase of the cell cycle.
Activation is the result of the stimulated exchange of GTP
for GDP catalyzed by guanine nucleotide-exchange
factors, such as Sos. The activation of membrane-bound
Ras by growth-factor and cytokine receptors is generally
achieved by the recruitment of Grb2–Sos complexes to the
receptors themselves, or to adaptor proteins such as Shc. A
primary target of activated Ras during growth-factor stimu-
lation is Raf, which is the first component of a protein
kinase cascade that leads to activation of the mitogen-acti-
vated protein (MAP) kinases ERK1 and ERK2 (ERK
standing for extracellular signal-regulated kinase; [1]). The
phosphorylation of transcription factors by these MAP
kinases results in the expression of immediate–early
response genes, such as c-fos, which are required for pro-
gression through early-G1 phase of the cell cycle.
Although these signalling events occur within minutes of
growth-factor stimulation, microinjection of neutralizing
anti-Ras antibodies in late-G1 phase blocks progression of
fibroblasts into S phase [2]. Furthermore, studies involv-
ing combinations of cell-cycle inhibitors and anti-Ras
microinjection clearly demonstrate that there are multiple
points in early and late-G1 phase at which Ras is required
[3]. These findings, together with the observations that
expression of oncogenic Ras increases cyclin D1 levels
and shortens G1 phase [4,5], and that Ras and cyclin D1
cooperate in cellular transformation assays [6,7], point to
an important role for Ras in regulating the progression
from G1 into S phase.
Results and discussion
A novel assay for activated Ras
Most previous analyses of Ras activation have measured
the GTP: GDP ratio of immunoprecipitated Ras following
32P radiolabelling of cells [8–11]. The ability of even very
low levels of radioisotopes to cause rapid cell-cycle arrest
(within a few hours) or apoptosis [12–14], however, pre-
cludes the use of such assays to measure Ras activity in
cycling cells. We therefore developed an assay that
exploits the known specificity of the interaction between
Ras–GTP and the Ras-binding domain (RBD) of Raf-1
[15–18] in order to detect activated Ras. Dialyzed deter-
gent lysates of HeLa cells were treated with or without
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guanine nucleotides and then incubated with GST–RBD
(a glutathione-S-transferase–RBD fusion protein) immobi-
lized on glutathione–Sepharose. Bound proteins were
eluted, and subjected to SDS–PAGE and western blotting
using anti-pan Ras antibodies. GST–RBD affinity precipi-
tated the GTPgS-bound form of Ras, but not GDP-bound
or nucleotide-free forms (Fig. 1a, lanes 1–3). Therefore, as
the Raf RBD has a significantly lower affinity for
Ras–GDP than for Ras–GTP, only Ras–GTP is detected
under the conditions of this assay.
Treatment of HeLa cells with epidermal growth factor
(EGF) greatly increased the affinity precipitation of Ras by
GST–RBD, whereas the recovery of Ras in anti-Ras
immunoprecipitates was unaltered by EGF treatment (Fig.
1b, lanes 1–4). In this experiment, ~40–50 % of total cellu-
lar Ras was activated by EGF treatment, in close agree-
ment with the level of Ras–GTP measured previously by
32P incorporation in EGF-stimulated Rat-1 fibroblasts [19].
The anti-Ras antibody 259, which blocks the Ras–Raf
interaction [20], blocked the affinity precipitation of Ras
by GST–RBD in the EGF-stimulated cells, whereas anti-
body 238, which does not block Ras–Raf binding, did not
(Fig. 1b, lanes 5,6). We did not detect co-immunoprecipi-
tation of Ras and Raf after EGF treatment using either
anti-Ras or anti-Raf antibodies under the conditions of this
assay (data not shown); therefore endogenous Raf does not
interfere with the binding of Ras–GTP to GST–RBD.
Inclusion of GDP or GTP in the lysis buffer did not affect
the affinity precipitation of Ras from EGF-treated or
untreated cells (Fig. 1c, lanes 1–6), showing that GTP
binding to Ras did not occur after lysis. In summary, the
assay rapidly and specifically detects cellular Ras–GTP and
changes in its levels in response to physiological stimuli.
Ras is activated during progression through G1 phase in
HeLa cells
To determine whether Ras activity is modulated during
progression through G1 phase, HeLa cells were released
from a mitotic arrest and analyzed for Ras activation at
time points thereafter. Figure 2a shows that the level of
Ras–GTP increased several-fold following exit from
mitosis, reaching a peak ~4 hours into G1 phase, and then
decreased as the cells approached the onset of S phase
(~10 h after mitosis, as determined by cell-sorting analy-
sis). The total levels of cellular Ras remained constant
during this period (data not shown). The pattern and
extent of Ras activation in mid-G1 phase was the same
when cells were grown in the presence or absence of
added serum (Fig. 2b, lanes 1–4; data not shown), or in
suspension or attached to plates (Fig. 2b, lanes 4,5; data
not shown). Furthermore, Ras activation during G1 phase
was blocked by inhibitors of protein synthesis and gene
transcription (Fig. 2b, lanes 5–7) and was not restored by
adding mid-G1 conditioned medium to serum-starved cells
(Fig. 2b, lanes 8,11,12). These results point towards a
mechanism of Ras activation that is integral to the cell-cycle
machinery and is not solely linked to receptor activation.
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An assay for activated Ras. (a) Dialyzed HeLa cell lysates were
incubated in the absence (lanes 1,4) or presence of GDP (lane 2) or
GTPgS (lane 3). Lysates were subjected to affinity precipitation (AP)
with GST–RBD (lanes 1–3) or immunoprecipitation (IP) with anti-Ras
antibodies (lane 4). Ras proteins were detected by immunoblotting
with monoclonal anti-Ras antibodies. (b) Serum-starved HeLa cells
were treated with (lanes 2,4–6) or without (lanes 1,3) 200 ng ml–1
EGF for 10 min before cell lysis. Lysates were subjected to
immunoprecipitation with anti-Ras antibodies (lanes 1,2), or affinity
precipitation with GST–RBD (lanes 3–6). Lanes 5,6: extracts were
preincubated with 4 mg of anti-Ras antibody 238 (lane 5) or anti-Ras
antibody 259 (lane 6) before precipitation. Ras proteins were detected
as in (a). (c) Serum-starved HeLa cells were treated without (lanes
1–3) or with (lanes 4–7) 200 ng ml–1 EGF for 10 min, lysed in lysis
buffer (lanes 1,4,7), or in lysis buffer containing 1 mM GDP (lanes 2,5)
or 0.1 mM GTPgS (lanes 3,6), and precipitated with GST–RBD (lanes
1–6) or GST alone (lane 7). Ras proteins were detected as in (a).
The activation of Ras by EGF and many other agonists
involves the binding of Grb2–Sos complexes to tyrosine-
phosphorylated Shc proteins. Treatment of serum-
starved HeLa cells or cells synchronized in mid-G1
phase (6 h after mitotic release) with EGF resulted in
rapid tyrosine phosphorylation of p46 and p52 Shc pro-
teins (Fig. 2c, middle panel, lanes 7,9). This was accom-
panied by Shc–Grb2 complex formation, as shown by the
co-immunoprecipitation of Grb2 in anti-Shc immunopre-
cipitates (Fig. 2c, lower panel, lanes 7,9). However, Ras
activation during G1 progression was not associated with
detectable tyrosine phosphorylation of Shc or with
Shc–Grb2 complex formation (lanes 1–6). The mecha-
nism of Ras activation in G1 phase therefore appears to
differ from Ras activation induced by EGF and many
other mitogens.
Activation of Ras in mid-G1 phase is uncoupled from 
ERK2 activation
Activation of Ras by growth factors leads to the rapid
activation of the MAP kinases ERK1 and ERK2. Acti-
vated RasL61, in which the glutamine at residue 61 is
replaced by leucine, strongly activates co-expressed ERK2
in HeLa cells [21]. To determine whether ERK2 activity
was stimulated in response to Ras activation during G1-
phase progression, HeLa cell extracts were analyzed for
Ras and ERK2 activity following mitotic release. ERK2
kinase activity — measured by in-gel kinase assay of anti-
ERK2 immunoprecipitates using myelin basic protein as a
substrate — increased within 2 hours of release from
mitosis and maintained about the same level of activity
throughout G1 phase, except for a small increase in activ-
ity near the G1/S transition (Fig. 3a, upper panel, lanes
1–9). In contrast, the level of Ras activation increased
through early-G1 phase, again reaching maximal levels
around mid-G1 (Fig. 3b). Interestingly, an in-gel kinase
assay (Fig. 3a, upper panel) and a gel mobility-shift assay
(Fig. 3a, lower panel) showed that the activation of ERK2
by EGF in mid-G1 cells was substantially lower than that
induced by EGF in serum-starved cells (Fig. 3a, compare
lanes 4 and 7 with 8 and 9), even though activation of Ras
(Fig. 3b, lanes 4,7–9) and tyrosine phosphorylation of Shc
(Fig. 2c) in response to EGF were similar in mid-G1 and
serum-starved cells. Because only a small fraction of
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Activation of Ras during G1 phase in HeLa cells. Synchronized cells
were produced by mitotic arrest using a thymidine–nocodazole double
block and released into G1 phase (in suspension culture, unless
otherwise indicated); unsynchronized cells were serum-starved and
treated with agonists. Extracts were prepared and subjected to affinity
precipitation or immunoprecipitation followed by immunoblot analysis
using anti-Ras antibodies. (a) Lanes 1–9, GST–RBD affinity
precipitates from cell lysates prepared at the indicated times after
release from mitotic arrest; lanes 10–12, GST–RBD affinity
precipitates from unsynchronized (lane 10) or serum-starved cells
treated for 10 min without (lanes 10,11) or with (lane 12) 100 ng ml–1
EGF; lane 13, unsynchronized cell lysate (50 % of the volume used in
affinity precipitations) subjected to immunoprecipitation using anti-Ras
antibodies; lane 14, whole cell lysate (WCL; 5 % of the volume used in
affinity precipitation). (b) Lanes 1–4, affinity precipitates from cells
released for 1 h (lanes 1,2) or 6 h (lanes 3,4) from mitotic arrest in
suspension culture in the presence (lanes 2,4) or absence (lanes 1,3)
of 10 % calf serum (CS); see Materials and methods for details. Lanes
5–7, affinity precipitates from cells released from mitotic arrest for 6 h
and allowed to attach to plates in the absence (lane 5) or presence of
25 mg ml–1 cycloheximide (CHX; lane 6) or 5 mg ml–1 actinomycin D
(Act.D; lane 7), added 45 min after release. Lanes 8–12, affinity
precipitates from serum-starved cells treated for 10 min in the absence
(lane 8) or presence of 100 ng ml–1 EGF (lane 9), 10 % serum (CS;
lane 10), or conditioned medium from the cells analyzed in lane 3 (G1
medium –CS; lane 11) or in lane 4 (G1 medium +CS; lane 12). (c)
Anti-Shc immunoprecipitates from cells released from mitotic arrest for
the indicated times (lanes 1–6), from cells relased from mitotic arrest
for 6 h and treated with 100 ng ml–1 EGF (lane 7), or from serum-
starved cells treated without (lane 8) or with (lanes 9,10) 100 ng ml–1
EGF. Lane 10, serum-starved cells treated with 100 ng ml–1 EGF and
immunoprecipitated in the absence of anti-Shc antibodies.
Immunoblots were probed with antibodies directed against Shc,
phosphotyrosine (PTyr) or Grb2.
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Relative activation of Ras and ERK kinases in HeLa cells during G1
phase. (a) Lanes 1–10, anti-ERK2 immunoprecipitates from cells
treated as described in lanes 1–10 in Fig. 2c. Immunoprecipitates
were subjected to an in-gel kinase assay using myelin basic protein as
substrate (upper panel), or immunoblotted with anti-ERK2 monoclonal
antibodies (lower panel). (b) Lanes 1–9, GST–RBD affinity
precipitates from the cells analyzed in lanes 1–9 of (a) immunoblotted
with anti-Ras antibodies.
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Relative activation of Ras and ERK kinases in NIH 3T3 cells during G1
phase. (a) NIH 3T3 cells were serum-starved 24 h and then treated
without (lanes 2,11) or with 10 % calf serum (lanes 3–10) or
100 ng ml–1 EGF (lane 12) for the indicated times. Upper panel:
GST–RBD affinity precipitates from cell lysates were immunoblotted
with anti-K-Ras antibodies. Lane 1 contains whole cell lysate (WCL;
5 % of the volume used in the affinity precipitations). Lower panel: cell
lysates were subjected to western immunoblotting using an antibody
specific for tyrosine phosphorylated, activated ERK1 and ERK2 (anti-
ERK-P). (b) NIH 3T3 cells were serum-starved and treated without
(lane 1) or with 20 % calf serum for 10 min (lane 2) or 4 h (lane 3), or
for 10 min with 50 ng ml–1 EGF (lane 4) or 10 ng ml–1 PDGF (lane 5).
Upper panel: GST–RBD affinity precipitates probed with anti-K-Ras
antibodies. Middle and lower panels: anti-ERK2 immunoprecipitates
probed with anti-phosphotyrosine (anti-PTyr) or anti-ERK2 antibodies.
ERK2 was activated in G1 phase, as indicated by the low
level of the mobility-shifted form on immunoblots (Fig.
3a, lower panel), these results indicate that Ras activation
was significantly uncoupled from ERK activation in mid-
G1 phase.
Ras is activated in mid-G1 phase in NIH 3T3 fibroblasts
To extend our observations, we examined Ras and ERK
activities during G1 progression in NIH 3T3 fibroblasts
released from quiescence by serum treatment. Under the
conditions used, the cells entered S phase approximately
12 hours after serum addition, as determined by bromod-
eoxyuridine incorporation (data not shown). The levels of
K-Ras (detected using a K-Ras-specific antibody which
offers greater signal resolution in these cells) increased
progressively during early-G1 phase, reaching maximal
levels around 4 hours after serum addition, and then
decreased towards basal levels as the cells approached S
phase (Fig. 4a, upper panel). As in the mitotic-release
experiments, maximal activation of ERK1 and ERK2 —
as determined by immunoblotting of cell lysates with an
antibody specific for tyrosine phosphorylated ERKs —
preceded peak K-Ras activation, occurring within
10 minutes of serum treatment (Fig. 4a, lower panel, lanes
1,2). Thereafter, these activities decreased during early-
G1 progression (Fig. 4a, lanes 2–10), in agreement with
other studies [22,23], such that activated ERKs were
barely detectable at the time of maximal K-Ras activation.
Analysis of anti-ERK2 immunoprecipitates, using a gel
mobility-shift assay and anti-phosphotyrosine antibodies
(Fig. 4b) or an in-gel kinase assay (data not shown),
revealed that treatment with serum, EGF or PDGF
resulted in the substantial activation of ERK2 (>50 %, as
determined by mobility shift) within 10 minutes, which
correlated with minor activation of K-Ras (Fig. 4, lanes
1,2,4,5). In sharp contrast, only a small fraction of ERK2
was activated 4 hours after serum treatment, when K-Ras
was maximally activated (Fig. 4, lane 3).
Conclusions
The assay described here rapidly and efficiently detects
functionally active cellular Ras and should therefore find
wide applicability in studies of normal and oncogenic Ras
function. We have exploited this assay to measure Ras
activation during progression through G1 phase and to
temporally correlate this with established upstream and
downstream events in Ras signalling. Following release
from mitosis, Ras became maximally activated in mid-G1
phase. This activation was not associated with the recruit-
ment of Grb2 by Shc, was dependent on gene transcrip-
tion and protein synthesis, and was apparently
independent of extracellular soluble ligands, suggesting
that Ras may be regulated by the cell-cycle machinery as
well as by receptor-mediated mechanisms. K-Ras activa-
tion also reached a maximum in mid-G1 phase in serum-
stimulated fibroblasts. Importantly, this occurred after the
largest increases in ERK activity, which occurred in very
early-G1 phase, regardless of whether cells were released
from mitosis or quiescence. This temporal disjunction
between activation of Ras and a well established effector
pathway raises the possibility that Ras targets other
pathways in mid-G1 phase that may be required for
progression into S phase (Fig. 5).
It has become clear that Ras uses multiple effectors to relay
mitogenic signals to different cellular pathways [24]. For
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Figure 5
A model for Ras function in G1 progression
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instance, effector domain mutants of activated Ras have
been identified that are defective for either ERK activation
or cytoskeleton reorganization [25]. Neither type of mutant
alone can stimulate DNA synthesis, but together they
promote progression into S phase. How these distinct Ras
effector pathways interact to result in mitogenesis is not yet
clear. We suggest that these pathways may be temporally
coordinated by Ras in a cell-cycle dependent manner.
Materials and methods
Cell culture and synchrony
HeLa S3 cells and NIH 3T3 fibroblasts were grown in DMEM contain-
ing 10 % calf serum. HeLa cells were arrested in mitosis using a thymi-
dine–nocodazole double block: cells growing in DMEM containing
10 % calf serum were incubated in 2 mM thymidine for 20–24 h,
washed with DMEM, trypsinized and replated; 0.1 mg ml–1 nocodazole
was added after 2 h and mitotic cells were collected by shake-off
12–14 h later. For mitotic release, cells were washed twice with
DMEM, resuspended in DMEM containing 10 % serum and incubated
in suspension in spinner culture (HeLa cells grow synchronously in sus-
pension; [26]) or allowed to re-attach to plates (in Fig. 2b, lanes 5–12).
HeLa and NIH 3T3 cells were incubated in DMEM without serum for
24 h before treatment with growth factors or serum.
Cell lysis, immunoprecipitations and kinase assays
Suspension and adherent cells were washed twice with ice-cold HBS.
In Fig. 1a, cells were lyzed in a solution containing 20 mM Hepes
(pH 7.5), 150 mM NaCl, 5 mM EDTA, 1 % NP-40, 10 mg ml–1 leu-
peptin and 10 mg ml–1 aprotinin, and the lysates were dialyzed exten-
sively against the same buffer without protease inhibitors. After clearing
by centrifugation, dialyzed lysates (0.3 ml) were incubated with or
without 1 mM GDP or 0.5 mM GTPgS for 10 min, and then with
10 mM MgCl2 for 60 min at room temperature. For affinity and immuno-
precipitations in the other figures, cells were lyzed in Mg2+-containing
lysis buffer (25 mM Hepes (pH 7.5), 150 mM NaCl, 1 % NP-40,
0.25 % Na deoxycholate, 10 % glycerol, 25 mM NaF, 10 mM MgCl2,
1 mM EDTA, 1 mM Na vanadate, 10 mg ml–1 leupeptin and 10 mg ml–1
aprotinin) at 0.4–0.8 ml per plate. Lysates were either used immedi-
ately or frozen in liquid nitrogen and stored at –70 °C until use. In Fig.
1, equal volumes of lysate were used for precipitations (0.3 ml for affin-
ity precipitations; 0.15 ml for immunoprecipitations). In other figures,
the protein concentrations of lysates were determined and equal
amounts of proteins were used. For immunoprecipitations, lysates were
incubated with 1 mg anti-Ras monoclonal antibody 238 (Santa Cruz)
for 60 min and then with Protein G–Sepharose (20 ml packed beads)
for 40 min. Shc proteins were immunoprecipitated with 1 mg anti-Shc
polyclonal antibody (Transduction Labs) for 4 h followed by collection
on protein A–Sepharose beads. ERK2 was immunoprecipitated for 4 h
with 0.5 mg anti-ERK R2 polyclonal antibody (UBI) plus 0.5 mg anti-
ERK2 antibody (sc-154; Santa Cruz) followed by collection on Protein
A–Sepharose beads. Although these antibodies recognize ERK1 and
ERK2, we only detected ERK2 in immunoprecipitates. All precipitates
were washed three times with lysis buffer containing 10 mM MgCl2
and bound proteins were eluted with SDS–PAGE sample buffer. For
anti-Shc immunoprecipitations, proteins were eluted in SDS-PAGE
sample buffer containing 20 mM N-ethyl maleimide (to prevent IgG
reduction and interference of heavy and light chains on blots). Proteins
were resolved on 10 % or 11 % acrylamide gels and subjected to
western blotting. Blots were probed with anti-pan Ras (Transduction
Labs), anti-K-Ras (sc-30) or anti-H-Ras (sc-29) monoclonal antibodies
(Santa Cruz), anti-Shc or anti-Grb2 monoclonal antibodies (Transduc-
tion Labs), anti-PTyr monoclonal antibody 4G10 (UBI), anti-ERK2 mon-
oclonal antibody (Transduction Labs), or with anti-phospho-MAP kinase
(anti-ERK-P) polyclonal antibodies (New England Biolabs); proteins
were detected using peroxidase-conjugated anti-mouse or anti-rabbit
antibodies and visualized by ECL.
In-gel kinase assays were performed on 10 % polyacrylamide mini-gels
containing 0.4 mg ml–1 myelin basic protein essentially as described
[27,28]. The kinase reaction was carried out for 40 min in 10 ml of
50 mM Tris–Cl (pH 7.5), 0.1 % NP-40, 1 mM DTT and 20 mM g-
[32P]ATP (~2.5 mCi mmol–1).
Assay for detection of activated Ras
To create an expression vector for the production of GST–RBD a
BamHI–HindIII fragment of plasmid pKScRaf1 (a gift from D. Morrison)
was blunt-ended and ligated into the SmaI site of pGEX-2T. pGEX-
RBD encodes amino acids 1–149 of cRaf-1 fused to GST. GST–RBD
expression in transformed Escherichia coli was induced with 1 mM
IPTG for 1–2 h and the fusion protein was purified on
glutathione–Sepharose beads. The beads were washed in a solution
containing 20 mM Hepes (pH 7.5), 120 mM NaCl, 10 % glycerol,
0.5 % NP-40, 2 mM EDTA, 10 mg ml–1 leupeptin and 10 mg ml–1 apro-
tinin, stored in the same buffer at 4 °C and used within 2–3 days of
preparation. For affinity precipitation lysates were incubated with
GST–RBD pre-bound to glutathione–Sepharose (~15 ml packed
beads, ~15–30 mg protein) for 30 min at 4 °C with rocking. Bound pro-
teins were eluted with SDS–PAGE sample buffer, resolved on 11 %
acrylamide gels and subjected to western blotting. Blots were probed
with anti-pan Ras (Transduction Labs), anti-K-Ras (sc-30) or anti-H-Ras
(sc-29) monoclonal antibodies (Santa Cruz).
Acknowledgements
We thank S. Bagrodia, R. Cerione, D. Laird and R. Resnick for comments
on the manuscript and discussions, and T. Thomas for help with figure
preparation. Supported by NIH grant CA 32317.
References
1. Avruch J, Zhang X-F, Kyriakis JM: Raf meets Ras: completing the
framework of a signal transduction pathway. Trends Biochem Sci
1994, 19:279–283.
2. Mulcahy LS, Smith MR, Stacey DW: Requirement for ras proto-
oncogene function during serum-stimulated growth of NIH 3T3
cells. Nature 1985, 313:241–243.
3. Dobrowolski S, Harter M, Stacey DW: Cellular ras activity is
required for passage through multiple points of the G-0-G-1
phase in BALB-c 3T3 cells. Mol Cell Biol 1994, 14:5441–5449.
4. Liu J-J, Chao J-R, Jiang M-C, Ng S-Y, Yen JJ-Y, Yang-Yen H-F: Ras
transformation results in an elevated level of cyclin D1 and
acceleration of G1 progression in NIH 3T3 cells. Mol Cell Biol
1995, 15:3654–3663.
5. Winston JT, Coats SR, Wang Y-Z, Pledger WJ: Regulation of the
cell cycle machinery by oncogenic ras. Oncogene
1996,12:127–134.
6. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA: Function
of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA
1994, 91:709–713.
7. Lovec H, Sewing A, Lubicello FC, Muller R, Moroy T: Oncogenic
activity cyclin D1 revealed through cooperation with Ha-ras; link
between cell cycle control and malignant transformation.
Oncogene 1994, 9:323–326.
8. Gibbs JB, Marshall MS, Scolnick EM, Dixon RAF, Vogel US:
Modulation of guanine nucleotides bound to Ras in NIH3T3 cells
by oncogenes growth factors and the GTPase-activating protein
gap. J Biol Chem 1990, 265:20437–20442.
9. Satoh T, Endo M, Nakafuku M, Nakamura S, Kaziro Y: Platelet-
derived growth factor stimulates formation of active p21ras-GTP
complex in Swiss mouse 3T3 cells. Proc Natl Acad Sci USA 1990,
87:5993–5997.
10. Gibbs JB: Determination of guanine nucleotides bound to Ras in
mammalian cells. Meth Enzymol 1995, 255:118–125. 
11. Satoh T, Kaziro Y: Measurement of Ras-bound guanine
nucleotides in stimulated hematopoietic cells. Meth Enzymol
1995, 255:149–155.
12. Wimber DE: Effects of intracellular irradiation with tritium. Adv
Radiat Biol 1964, 1:85–115. 
13. Dover R, Jayaram Y, Patel K, Chinery R: p53 expression in cultured
cells following radioisotope labelling. J Cell Sci 1994,
107:1181–1184. 
1626 Current Biology 1996, Vol 6 No 12
14. Yeargin J, Haas M: Elevated levels of wild-type p53 induced by
radiolabelling of cells leads to apoptosis or sustained growth
arrest. Curr Biol 1995, 5:423–431.
15. Chuang E, Barnard D, Hettich L, Zhang X-F, Avruch J, Marshall MS:
Critical binding and regulatory interactions between Ras and Raf
occur through a small, stable N-terminal domain of Raf and
specific Ras effector residues. Mol Cell Biol 1994, 14:5218–5325. 
16. Pumiglia K, Chow Y-H, Fabian J, Morrison D, Decker S, Jove R: Raf-1
N-terminal sequences necessary for Ras–Raf interaction and
signal transduction. Mol Cell Biol 1995, 15:398–406. 
17. Herrmann C, Martin GA, Wittinghofer A: Quantitative analysis of the
complex between p21ras and the Ras-binding domain of the
human Raf-1 protein kinase. J Biol Chem 1995, 270:2901–2905. 
18. Nassar N, Horn G, Herrmann C, Scherer A, McCormick, Wittinghofer
A; The 2.2 Å crystal structure of the Ras-binding domain of serine-
threonine kinase c-Raf1 in complex with Rap1A and a GTP
analogue. Nature 1995, 375:554–560.
19. Hallberg B, Rayter SI, Downward J: Interaction of Ras and Raf in
intact mammalian cells upon extracellular stimulation. J Biol
Chem 1994, 269:3913–3916.
20. Warne PH, Vicinia PR, Downward J: Direct interaction of Ras and
the amino-terminal region of Raf-1 in vitro. Nature 1993,
364:352–355.
21. Minden A, Lin A, Claret F-X, Abo A, Karin M: Selective activation of
the JNK signalling cascade and c-Jun transcriptional activity by
the small GTPases Rac and Cdc42Hs. Cell 1995, 81:1147–1157.
22. Edelmann HML, Kuhne C, Petritsch C, Ballou LM: Cell cycle
regulation of p70 S6 kinase and p42/p44 mitogen-activated
protein kinases in Swiss mouse 3T3 fibroblasts. J Biol Chem
1996, 271:963–971.
23. Bennett AM, Hausdorff SF, O’Reilly AM, Freeman Jr RM, Neel BG:
Multiple requirements for SHPTP2 in epidermal growth factor-
mediated cell cycle progression. Mol Cell Biol 1996,
16:1189–1202.
24. Marshall CJ: Ras effectors. Curr Opin Cell Biol 1996, 8:197–204.
25. Joneson T, White MA, Wigler MH, Bar Sagi D: Stimulation of
membrane ruffling and MAP kinase activation by distinct effectors
of RAS. Science 1996, 271:810–812.
26. Heintz N, Sive HL, Roeder RG: Regulation of human histone gene
expression; kinetics of accumulation and changes in the rate of
synthesis and in the half-lives of individual histone mRNAs during
the HeLa cell cycle. Mol Cell Biol 1983, 3:539–550.
27. Kameshita I, Fujisawa H: A sensitive method for detection of
calmodulin-dependent protein kinase II activity in sodium dodecyl
sulfate–polyacrylamide gel. Anal Biochem 1989, 183:139–143.
28. Hibi M, Lin A, Smeal T, Minden A, Karin M: Identification of a
oncoprotein- and UV-responsive protein kinase that binds and
potentiates the c-Jun activation domain. Genes Dev 1993,
7:2135–2148.
Research Paper  Ras activation during the cell cycle Taylor and Shalloway    1627
